Nicotine and cotinine replacement when nicotine nasal spray is used to quit smoking.
Nicotine nasal spray (NNS) is generally considered to be an effective smoking cessation aid, but all studies to date of NNS effectiveness have also utilized group therapy sessions or frequent laboratory visits to support their subjects' stop smoking efforts. We studied 50 volunteers before they attempted to quit smoking and again at 1, 2 and 3 months after they received NNS to assist them in quitting smoking. No other stop smoking intervention was used, which more closely mimics the common practice of many individuals trying to stop smoking with the aid of a nicotine replacement product but without other supportive interventions. We found that 50% of the subjects quit smoking for the first month, 34% were still abstinent after 2 months and 32% quit smoking for 3 months. Those who quit smoking for the entire 3 months and who continued regular NNS use throughout had 67% cotinine replacement at the end of the first month, while another group which quit smoking for only the first month with the aid of NNS had 42% cotinine replacement at the end of that month. Our data confirm that NNS is an effective smoking cessation aid, but our abstinent rate at 3 months is slightly lower than in other studies in which group therapy was provided. Our data also indicate that higher NNS-induced cotinine replacement during the first month of quitting smoking (suggesting more frequent use of NNS) is associated with longer term quit-smoking success rate.
Department of Medicine, University of Alberta, Edmonton, Canada. rjones@sol.uah.ualberta.ca
R L
RL
Jones
A
A
Nguyen
S F
SF
Man
D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D002248:Carbon Monoxide / Q000097:blood; D003367:Cotinine / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D016540:Smoking Cessation / Q000379:methods*
D000336:Aerosols; D018722:Nicotinic Agonists; D009538:Nicotine; D002248:Carbon Monoxide; D003367:Cotinine